Archive · 23 Jul 2026
Cipla Q1 Profit Drops 39%
Cipla, a big Indian medicine company, made less money in the first three months of 2026.
They earned Rs 785.55 crore, which is 39% less than last year.
This happened because they sold fewer medicines in North America, and their costs went up.
However, their business in India did well, selling more medicines than ever before.
They also got a new finance boss named Dinesh Jain.
Cipla's consolidated net profit for Q1 FY27 declined by 39% to Rs 785.55 crore.
Total revenue from operations stood at Rs 7,119.28 crore, up from Rs 6,957.47 crore in the same period last year.
Total expenses increased to Rs 6,248.25 crore, compared to Rs 5,446.1 crore in Q1 FY26.
North American sales decreased by 21% to Rs 1,532 crore.
The 'One-India' business recorded its highest quarterly sales, growing by 12% to Rs 3,452 crore.
- Who
- Cipla Ltd
- What
- Reported a 39% drop in consolidated net profit for Q1 FY27
- When
- First quarter ended June 2026
- Where
- Primarily impacted by North American market
- Why
- Due to a 21% decrease in North American sales and increased operational expenses
Market Challenges
Domestic Growth
North American Sales Decline
Market Challenges
A 21% decrease in North American sales significantly impacted overall profitability.
Domestic Growth
The 'One-India' business recorded its highest quarterly sales, growing by 12%.
- Consolidated Net Profit
- Rs 785.55 crore
- Total Revenue
- Rs 7,119.28 crore
- Total Expenses
- Rs 6,248.25 crore
- North American Sales
- Rs 1,532 crore
- One-India Sales
- Rs 3,452 crore
- New CFO
- Dinesh Jain
- Effective Date for CFO
- July 24, 2026